Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VIVO

Meridian Bioscience (VIVO) Stock Price, News & Analysis

Meridian Bioscience logo

About Meridian Bioscience Stock (NASDAQ:VIVO)

Advanced Chart

Key Stats

Today's Range
$33.97
$33.97
50-Day Range
$33.00
$33.97
52-Week Range
$20.35
$34.38
Volume
N/A
Average Volume
973,737 shs
Market Capitalization
$1.50 billion
P/E Ratio
35.02
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Stock News Headlines

Meridian Bioscience Inc (VIVO)
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Meridian Growth Legacy MERDX
See More Headlines

VIVO Stock Analysis - Frequently Asked Questions

Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings data on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.03. The business earned $76.20 million during the quarter, compared to the consensus estimate of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%.

Meridian Bioscience subsidiaries include Exalenz Bioscience.

Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/12/2021
Today
5/10/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:VIVO
Employees
702
Year Founded
1977

Profitability

Trailing P/E Ratio
35.02
Forward P/E Ratio
40.93
P/E Growth
N/A
Net Income
$42.46 million
Pretax Margin
16.31%

Debt

Sales & Book Value

Annual Sales
$333.02 million
Cash Flow
$1.78 per share
Price / Cash Flow
19.13
Book Value
$8.41 per share
Price / Book
4.04

Miscellaneous

Free Float
42,996,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.23

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:VIVO) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners